Time New York: Mon 10 Dec 00:18 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Bristol-Myers Collaborates With Harvard Fibrosis Network

Zacks

Bristol-Myers Squibb Company BMY entered into a research collaboration agreement with Harvard Fibrosis Network of the Harvard Stem Cell Institute.

Both companies have teamed up to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.

Per the terms of the agreement, leading academic investigators of hepatic and cardiac fibrosis from the Harvard Fibrosis Network will collaborate with leading scientists from Bristol-Myers Squibb on four projects over three years. These projects will focus on applied fibrosis biology, identification of noninvasive biomarkers, and novel targets for potential anti-fibrotic therapies, in the areas of hepatic and cardiac fibrosis.

Bristol-Myers is building a robust pipeline of investigational candidates to address areas of high unmet need in fibrosis, including nonalcoholic steatohepatitis (“NASH”) and idiopathic pulmonary fibrosis (“IPF”).


Bristol-Myers’ blockbuster drug Opdivo continues to perform well. Several label expansion applications for Opdivo are under review in the United States and Europe. Potential approval will boost the prospects of the drug further.

Shares of the company have rallied 14.3% in the past year, outperforming the industry’s gain of 10.8%.

However, with generic competition looming large over the company, Bristol-Myers’ pipeline needs to deliver. Hence, the company is looking to diversify its portfolio in the promising space like NASH.

In 2017, Bristol-Myers extended its strategic partnership with TARGET PharmaSolutions, Inc. The partnership has been extended for TARGET-NASH for a multi-year deal.

We note that both companies announced two new collaborations in November 2016 for the treatment of NASH and HCC.

Bristol-Myers already has a mid-stage candidate in the NASH space. BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism, in patients with biopsy-confirmed NASH (F1-F3) achieved its primary endpoint of significant reduction in liver fat versus placebo in April. The company was entitled the rights to research, develop and commercialize BMS-986036 from Ambrx, Inc.

Other major companies with promising candidates for NASH are Intercept Pharma ICPT, Gilead Sciences GILD and Novartis NVS.

Zacks Rank

Bristol-Myers carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>










Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.